Cargando…

Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study

INTRODUCTION: The effects of switching DPP-4 inhibitors in type 2 diabetes mellitus (T2DM) patients are being widely studied. However, information of which factors affect the therapeutic response is limited. We evaluated the difference in HbA1c lowering effect by comorbidity and other variables afte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sang-Yong, Kim, Sungrae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880082/ https://www.ncbi.nlm.nih.gov/pubmed/36417158 http://dx.doi.org/10.1007/s13300-022-01339-4

Ejemplares similares

Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis
por: Lee, Subin, et al.
Publicado: (2019)

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Chiba, Yukari, et al.
Publicado: (2018)

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
por: Furuhashi, Masato, et al.
Publicado: (2022)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study
por: Hashimoto, Naoki, et al.
Publicado: (2015)

Dipeptidyl peptidase‐4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
por: Abe, Takahiro, et al.
Publicado: (2021)

Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study
por: Yoshizawa, Yuta, et al.
Publicado: (2021)

Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI
por: Xue, Jujun, et al.
Publicado: (2020)

Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
por: Kim, Nam Hoon, et al.
Publicado: (2017)

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2019)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
por: Nishio, Shinya, et al.
Publicado: (2015)

Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study
por: Du, Guoli, et al.
Publicado: (2020)

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
por: Furuhashi, Masato, et al.
Publicado: (2020)

Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors
por: Del Prato, Stefano, et al.
Publicado: (2017)

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
por: Saini, Kunika, et al.
Publicado: (2023)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury
por: Li, Qi, et al.
Publicado: (2017)

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2022)

Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2020)

Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy
por: Kaku, Kohei, et al.
Publicado: (2014)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients
por: Chen, Hsin-Hung, et al.
Publicado: (2015)

Ease of Use, Preference, and Safety of the Recombinant Human Growth Hormone Disposable Pen Compared with the Reusable Device: A Multicenter, Single-Arm, Open-Label, Switch-Over, Prospective, Phase IV Trial
por: Lee, Ji-Eun, et al.
Publicado: (2019)

Genetic variation in DPP-IV gene linked to predisposition of T2DM: A case control study
por: Bhargave, Archna, et al.
Publicado: (2022)

Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes
por: Yamazaki, Shunsuke, et al.
Publicado: (2022)

Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
por: Kang, Yu Mi, et al.
Publicado: (2019)

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2020)

Effects of anagliptin on the stress induced accelerated senescence of human umbilical vein endothelial cells
por: Kang, Seon Mee, et al.
Publicado: (2021)

Combined exercise and nutrition intervention for older women with spinal sarcopenia: an open-label single-arm trial
por: Kim, Seungcheol, et al.
Publicado: (2023)

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
por: Otsubo, Tempei, et al.
Publicado: (2018)

Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
por: Honda, Yasushi, et al.
Publicado: (2017)

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
por: Wirth, Lori J., et al.
Publicado: (2021)

Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study
por: Matsumura, Tsuyoshi, et al.
Publicado: (2022)

F45. THE EFFICACY AND SAFETY OF BLONASERIN AFTER SWITCHING FROM OTHER ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC INPATIENTS: AN OPEN-LABEL, MULTI-CENTER TRIAL
por: Yoon, Bo-Hyun, et al.
Publicado: (2018)

Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study
por: Lee, Mi Young, et al.
Publicado: (2014)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Anagliptin alleviates lipopolysaccharide-induced inflammation, apoptosis and endothelial dysfunction of lung microvascular endothelial cells
por: Zhang, Jingli, et al.
Publicado: (2021)

Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
por: Jung, Ki Sun, et al.
Publicado: (2018)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study
por: Liang, Ying, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eno7gvpnt7hj3leelnikgkte78